On the afternoon of May 1, the clinical study of the inactivated vaccine of the New Coronavirus variant developed by Sinopharm Group's China Bio-Beijing Institute of Biological Products officially completed the first dose of vaccination in Hangzhou, Zhejiang Province. It is also the world's first inactivated covid-19 vaccine against the Semickon variant to enter clinical trials.
Recently, the new crown pneumonia epidemic has appeared in many parts of The country, and the main "culprit" is the Aomi Kerong variant strain, which has the characteristics of strong contagiousness, short incubation period, short transmission time, and difficult prevention and control. On April 26, the State Drug Administration of China officially approved the inactivated covid-19 vaccine developed by Kexing Holdings Biologics and Sinopharm Group China Biologics based on the Omicron variant (hereinafter referred to as the Omicron) (hereinafter referred to as the Omicron) into clinical research to evaluate the safety and immunogenicity of the new coronavirus variant vaccine in various populations.
After obtaining the clinical approval, the National Drug Clinical Trial Institution of Shulan (Hangzhou) Hospital immediately carried out the preparatory work before the project started, completed the review of the Drug Clinical Trial Ethics Committee in the shortest possible time and obtained the ethical approval, and the clinical research was officially launched on May 1. The clinical study of the inactivated vaccine of the new crown virus will be in the form of a non-randomized, open-ended, externally controlled study.
The clinical study of the Olympic vaccine in Shulan (Hangzhou) Hospital requires two doses, and the safety and immunogenicity of the Austrian vaccine in people aged 18 years and above who have not been vaccinated against the new crown virus vaccine will be evaluated. After this clinical study data is approved, the blank population that has not been vaccinated against COVID-19 can be directly vaccinated with the Austrian strain vaccine.
"The development of vaccines for the variant of Omi kerong is very important, of course, the original vaccine is still effective, but after the development of vaccines for mutant strains, there may be better immune effects." This also proves the speed of China's anti-epidemic work and China's efficiency. Li Lanjuan, an academician of the Chinese Academy of Engineering, said that she believes that through rigorous clinical research, the safety and efficacy of vaccines can be further proved to ensure the application of vaccines in the future.
Zhang Yuntao, chief scientist and vice president of China Biology, previously told reporters that the Austrian vaccine systematically did animal immunogenicity evaluation before being approved for clinical research, and used serum obtained from immune animals to do in vitro cross-neutralization experiments on various variants that were highly concerned by WHO. Judging from the results, the Olympian vaccine has a good neutralization activity against the Aomi Kerong variant strain, and the neutralization activity of beta, Delta and prototype strains has also been improved, and the effect is still very ideal.
Sichuan Observation (Source: Beijing Daily)